Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Therapeutic Autologous Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

This study has been terminated.
National Cancer Institute (NCI)
Information provided by:
Fred Hutchinson Cancer Research Center Identifier:
First received: January 24, 2003
Last updated: July 12, 2011
Last verified: July 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2011
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)